The Rundown
The Rundown

Deep Dive: Can Hims Survive the GLP-1 Crackdown?

March 14, 2026

AI Summary

5 min read

🎙️ The Voices & The Context

  • The Format: This is a solo-hosted, narrative-style podcast episode from "The Rundown." It’s a deep dive, structured like a business documentary—part history lesson, part stock analysis, part thriller.
  • The Key Players:
    • The Host: An unnamed narrator who acts as a financial storyteller. They’re engaging, slightly skeptical, and have a clear "I told you so" energy about the hype. They break down complex business moves into digestible drama.
  • The Vibe: Intense & Educational. It feels like a high-stakes business thriller. The host walks you through a rollercoaster of regulatory loopholes, legal brawls, and a shocking corporate plot twist. It’s fun because it’s real.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

What you'll learn

  • 1 (00:00) **Introduction: Hims & Hers (HIMS) Stock Deep Dive**
  • 2 (00:37) **The Backstory: Founding & Early Success**
  • 3 (01:36) **The GLP-1 Pivot: Entering the Weight Loss Market**
  • 4 (02:52) **The Peak: Super Bowl Ad & All-Time Highs**
  • 5 (03:06) **The Fall: FDA Shortage Removal & Legal Threats**
  • 6 (05:12) **The Lawsuit & Stock Plunge**
  • 7 (05:34) **The Breakthrough: Novo Nordisk Partnership (Bull Case)**

+ Full timestamped outline available in the app

Show Notes

In this deep dive, Zaid breaks down how Hims became one of the hottest stocks in the market during the GLP-1 boom, and why the company suddenly found itself in the middle of an FDA crackdown and a legal fight with Novo Nordisk. He also dives into the bull case, the bear case, and whether Hims can actually build a lasting digital healthcare business from here.

The Rundown

More from this podcast

The Rundown →